High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)

Launched by CLINIQUE DE RETINE DE L'EST · Aug 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat wet age-related macular degeneration (wAMD), a condition that affects the eyes and can cause vision loss. The study compares two different schedules of giving a higher dose of the medicine EYLEA® (called EYLEA® HD) to patients who have already been treated with the regular dose of EYLEA®. The goal is to find out which treatment plan works best for people switching to the higher dose.

To join this study, you must be over 18 years old and have wAMD. You also need to have already received at least five injections of the regular EYLEA® medicine (three at the start and two as ongoing treatment). The trial will include about 180 patients and take place in Montreal, Canada. Participants can expect to receive injections of EYLEA® HD and follow-up visits to monitor their eye health. People with other eye conditions, recent laser treatments, or who are pregnant cannot join. This study is important because it could help doctors decide the best way to give this higher dose treatment to improve vision for people with wAMD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over the age of 18
• • Patients with neovascular AMD
• • Patients who have received aflibercept 2mg for a minimum of 3 loading injections plus 2 maintenance injections.
• • Can include 1 or 2 eyes per patient if one or both meet study criteria.
• Exclusion Criteria:
• * Patients with other maculopathy, including but not limited to:
• • Polypoidal choroidal vasculopathy
• • Macular dystrophies (ie. Pattern dystrophy, central areolar etc.)
• • Toxic/drug induced maculopathies
• • Disciform scar
• • Subfoveal atrophy
• • Previous Photodynamic Therapy (PDT) or focal laser
• • Is currently enrolled in another clinical study or observational study
• • Active use of a different agent in the fellow eye, to avoid cross-over effects of anti Vascular Endothelial Growth Factor (VEGF) administration to the fellow eye
• • If the patient is pregnant